Cancer immunology, immunotherapy : CII · 2026
Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Weber Moritz, Freiherr von Hammerstein-Equord Alexander, Weinreich Manuela, Andreas Stefan, Rittmeyer Achim
Аннотация
INTRODUCTION: In advanced non-small cell lung cancer (NSCLC), nivolumab plus ipilimumab with platinum-based chemotherapy (NIC) and pembrolizumab with platinum-based chemotherapy (PC) are commonly used treatment options. We conducted a single-center retrospective analysis comparing the two options under real-world conditions in Germany.
METHODS: We collected data from patients whose treatment was initiated between July 2018 and June 2023. Primary endpoints were overall survival and safety. Categorical data were compared using the chi-squared test or Fisher's exact test. Overall survival was compared using the Kaplan-Meier method and the log-rank test.
RESULTS: 200 patients, 77 treated with NIC and 123 treated with PC, were included. Baseline characteristics were unbalanced with significantly more older, squamous, and PD-L1-negative cases in the NIC group. Median overall survival (OS) and time to treatment discontinuation (TTD) were not significantly different in the NIC and PC groups (13.6 vs. 14.1 months / 5.8 vs. 6.2 months). Clinically significant adverse events (AEsi), related treatment discontinuations, and treatment-related deaths also did not differ significantly (p = 0.885/p = 1.000/p = 0.709). There were more immune-related AEsi in the NIC group (p = 0.001) and more chemo-related AEsi in the PC group (p < 0.001).
CONCLUSIONS: NIC and PC seem to be equally supportable options in the treatment of advanced NSCLC. Further analyses are needed to validate our findings.
METHODS: We collected data from patients whose treatment was initiated between July 2018 and June 2023. Primary endpoints were overall survival and safety. Categorical data were compared using the chi-squared test or Fisher's exact test. Overall survival was compared using the Kaplan-Meier method and the log-rank test.
RESULTS: 200 patients, 77 treated with NIC and 123 treated with PC, were included. Baseline characteristics were unbalanced with significantly more older, squamous, and PD-L1-negative cases in the NIC group. Median overall survival (OS) and time to treatment discontinuation (TTD) were not significantly different in the NIC and PC groups (13.6 vs. 14.1 months / 5.8 vs. 6.2 months). Clinically significant adverse events (AEsi), related treatment discontinuations, and treatment-related deaths also did not differ significantly (p = 0.885/p = 1.000/p = 0.709). There were more immune-related AEsi in the NIC group (p = 0.001) and more chemo-related AEsi in the PC group (p < 0.001).
CONCLUSIONS: NIC and PC seem to be equally supportable options in the treatment of advanced NSCLC. Further analyses are needed to validate our findings.